Drug intelligence / Profile preview

milbemycin oxime + praziquantel

Development stage
Unknown
Lead developer
Elanco
Modality
Small Molecules
Administration
Oral
01

Overview

Milbemycin oxime + praziquantel is a veterinary pharmaceutical combination used primarily in dogs (and sometimes cats) for the prevention of heartworm disease and for the treatment and control of multiple gastrointestinal helminth infections, including adult hookworms, roundworms, whipworms, and tapeworms. Milbemycin oxime works as a macrocyclic lactone endectocide by binding to glutamate-gated chloride channels in nematodes and arthropods, leading to paralysis and death of susceptible parasites. Praziquantel is an isoquinoline-pyrazine anthelmintic, increasing the permeability of cell membranes to calcium, resulting in paralysis and death of tapeworms. This combination is formulated as a flavored chewable tablet for oral administration, typically given monthly. The combination is approved for use in dogs and puppies 6 weeks of age and older and weighing at least 2 lbs.

Brand names
MilbemaxProvectra
Other names
milbemycin oxime-praziquantel combinationmilbemycin with praziquantel
02

Targets

Cavβ (Voltage-gated calcium channel beta subunit)GluCl (Glutamate-gated chloride channel)RDL (Insect GABA-gated chloride channel)

Beyond the preview

Go deeper on milbemycin oxime + praziquantel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on milbemycin oxime + praziquantel.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call